secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001999371-25-011510
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix receives FDA approval of Tonmya (cyclobenzaprine HCl) for fibromyalgia in adults
--------------------------------------------------------------------------------

- FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for treatment of fibromyalgia in adults.
- Product launch and commercialization strategy underway; commercial team led by Thomas Englese.
- Webcast and conference call held August 18, 2025 to discuss approval and go-to-market plan.
- Management presented on product label, market opportunity, and key clinical data from TNX-102 SL trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011510/0001999371-25-011510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011510/tnxp-8k_081825.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-011510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer